Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
21592611

DOI
10.1016/j.lungcan.2011.04.010

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Carcinoma, Non-Small-Cell Lung /economics /pathology /physiopathology; Erlotinib Hydrochloride; France; Germany; Glutamates; Guanine /analogs & derivatives; Italy; Pemetrexed; Quinazolines; Spain

AccessionNumber
22012010862

Date bibliographic record published
06/02/2013